Latest Octagon Capital Advisors LP Stock Portfolio
Octagon Capital Advisors LP Performance:
2025 Q3: 72.16%YTD: 60.31%2024: -10.25%
Performance for 2025 Q3 is 72.16%, and YTD is 60.31%, and 2024 is -10.25%.
About Octagon Capital Advisors LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Octagon Capital Advisors LP reported an equity portfolio of $659.8 Millions as of 30 Sep, 2025.
The top stock holdings of Octagon Capital Advisors LP are , , GOSS. The fund has invested 17% of it's portfolio in ABIVAX SA and 14.4% of portfolio in DIANTHUS THERAPEUTICS INC.
The fund managers got completely rid off VERONA PHARMA PLC (VRNA), ARS PHARMACEUTICALS INC (SBTX) and ATYR PHARMA INC (LIFE) stocks. They significantly reduced their stock positions in NUVATION BIO INC (NUVB), TAYSHA GENE THERAPIES INC (TSHA) and TREVI THERAPEUTICS INC (TRVI). Octagon Capital Advisors LP opened new stock positions in BRIDGEBIO ONCOLOGY THERAPEUT, CIDARA THERAPEUTICS INC (CDTX) and PEPGEN INC (PEPG). The fund showed a lot of confidence in some stocks as they added substantially to KYMERA THERAPEUTICS INC (KYMR), OCULAR THERAPEUTIX INC (OCUL) and PHARVARIS N V (PHVS).
The top stock holdings of Octagon Capital Advisors LP are , , GOSS. The fund has invested 17% of it's portfolio in ABIVAX SA and 14.4% of portfolio in DIANTHUS THERAPEUTICS INC.
The fund managers got completely rid off VERONA PHARMA PLC (VRNA), ARS PHARMACEUTICALS INC (SBTX) and ATYR PHARMA INC (LIFE) stocks. They significantly reduced their stock positions in NUVATION BIO INC (NUVB), TAYSHA GENE THERAPIES INC (TSHA) and TREVI THERAPEUTICS INC (TRVI). Octagon Capital Advisors LP opened new stock positions in BRIDGEBIO ONCOLOGY THERAPEUT, CIDARA THERAPEUTICS INC (CDTX) and PEPGEN INC (PEPG). The fund showed a lot of confidence in some stocks as they added substantially to KYMERA THERAPEUTICS INC (KYMR), OCULAR THERAPEUTIX INC (OCUL) and PHARVARIS N V (PHVS).
Octagon Capital Advisors LP Annual Return Estimates Vs S&P 500
Our best estimate is that Octagon Capital Advisors LP made a return of 72.16% in the last quarter. In trailing 12 months, it's portfolio return was 57.48%.
New Buys
| Ticker | $ Bought |
|---|---|
| bridgebio oncology therapeut | 12,079,200 |
| cidara therapeutics inc | 9,576,000 |
| pepgen inc | 3,234,000 |
| structure therapeutics inc | 3,220,000 |
New stocks bought by Octagon Capital Advisors LP
Additions
| Ticker | % Inc. |
|---|---|
| kymera therapeutics inc | 35.34 |
| ocular therapeutix inc | 8.21 |
| pharvaris n v | 7.43 |
| abivax sa | 4.58 |
| cogent biosciences inc | 4.02 |
| dianthus therapeutics inc | 3.2 |
| arrivent biopharma inc | 1.28 |
Additions to existing portfolio by Octagon Capital Advisors LP
Reductions
| Ticker | % Reduced |
|---|---|
| nuvation bio inc | -65.76 |
| nuvation bio inc | -32.44 |
| taysha gene therapies inc | -27.99 |
| trevi therapeutics inc | -23.34 |
| merus n v | -20.82 |
| centessa pharmaceuticals plc | -19.42 |
| neurogene inc | -16.83 |
| gossamer bio inc | -7.08 |
Octagon Capital Advisors LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| atyr pharma inc | -19,367,400 |
| ars pharmaceuticals inc | -23,557,500 |
| tourmaline bio inc | -14,471,000 |
| erasca inc | -889,000 |
| kalaris therapeutics inc | -961,200 |
| verona pharma plc | -31,873,500 |
| helix acquisition corp ii | -2,662,500 |
| moonlake immunotherapeutics | -6,985,600 |
Octagon Capital Advisors LP got rid off the above stocks
Sector Distribution
Octagon Capital Advisors LP has about 55.3% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 55.3 |
| Others | 44.7 |
Market Cap. Distribution
Octagon Capital Advisors LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 44.7 |
| SMALL-CAP | 29.6 |
| MICRO-CAP | 14.1 |
| MID-CAP | 10.9 |
Stocks belong to which Index?
About 22.9% of the stocks held by Octagon Capital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 77.1 |
| RUSSELL 2000 | 22.9 |
Octagon Capital Advisors LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Octagon Capital Advisors LP
Octagon Capital Advisors LP has 26 stocks in it's portfolio. About 71.3% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. was the most profitable stock for Octagon Capital Advisors LP last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| APLS | apellis pharmaceuticals inc | 3.10 | 903,500 | 20,446,200 | unchanged | 0.00 | ||
| CDTX | cidara therapeutics inc | 1.45 | 100,000 | 9,576,000 | new | |||
| CNTA | centessa pharmaceuticals plc | 3.05 | 830,000 | 20,127,500 | reduced | -19.42 | ||
| COGT | cogent biosciences inc | 6.26 | 2,874,110 | 41,272,200 | added | 4.02 | ||
| CRBP | corbus pharmaceuticals hldgs | 2.14 | 1,115,000 | 14,104,800 | unchanged | 0.00 | ||
| DBVT | dbv technologies s a | 1.54 | 1,018,020 | 10,180,200 | unchanged | 0.00 | ||
| ERAS | erasca inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| GOSS | gossamer bio inc | 6.80 | 17,050,000 | 44,841,500 | reduced | -7.08 | ||
| KALV | kalvista pharmaceuticals inc | 2.35 | 1,273,330 | 15,509,200 | unchanged | 0.00 | ||
| KYMR | kymera therapeutics inc | 3.09 | 360,000 | 20,376,000 | added | 35.34 | ||
| LIFE | atyr pharma inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MLTX | moonlake immunotherapeutics | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MNMD | mind medicine mindmed inc | 3.81 | 2,130,000 | 25,112,700 | unchanged | 0.00 | ||
| MRUS | merus n v | 4.39 | 308,000 | 28,998,200 | reduced | -20.82 | ||
| NUVB | nuvation bio inc | 1.48 | 2,633,330 | 9,743,340 | reduced | -65.76 | ||
| NUVB | nuvation bio inc | 0.06 | 104,112 | 385,214 | reduced | -32.44 | ||
| OCUL | ocular therapeutix inc | 4.65 | 2,624,000 | 30,674,600 | added | 8.21 | ||
| PEPG | pepgen inc | 0.49 | 700,000 | 3,234,000 | new | |||
| PHVS | pharvaris n v | 2.73 | 722,595 | 18,028,700 | added | 7.43 | ||
| SBTX | ars pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||